Drug Type Antibody drug conjugate (ADC) |
Synonyms Sac-TMT, TROP-2-targeted antibody-drug conjugate + [6] |
Target |
Mechanism Trop-2 modulators(Tumor-associated calcium signal transducer 2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationBreakthrough Therapy (CN), Priority Review (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | NDA/BLA | CN | 11 Dec 2023 | |
Endometrial Carcinoma | Phase 3 | JP | 06 Dec 2023 | |
Endometrial Carcinoma | Phase 3 | DK | 06 Dec 2023 | |
Endometrial Carcinoma | Phase 3 | CA | 06 Dec 2023 | |
Endometrial Carcinoma | Phase 3 | CZ | 06 Dec 2023 | |
Endometrial Carcinoma | Phase 3 | AT | 06 Dec 2023 | |
Endometrial Carcinoma | Phase 3 | IT | 06 Dec 2023 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | CN | 19 Oct 2023 | |
EGFR positive Non-squamous non-small cell lung cancer | Phase 3 | CN | 29 Jun 2023 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | CN | 26 Jun 2023 |
Phase 2 | 43 | (luxwnlamfn) = wyparxhrtu lncnkxvwtk (fophwitrdj ) View more | Positive | 26 May 2023 | |||
(EGFR wild type) | (luxwnlamfn) = qsroiuxgyq lncnkxvwtk (fophwitrdj ) View more | ||||||
NCT05347134 (PRNewswire) Manual | Phase 3 | Triple Negative Breast Cancer Third line | - | (iwehzddmds) = 达到了主要研究终点 sridkglbzm (bqdwlegopg ) Met | Positive | 14 Aug 2023 | |
Not Applicable | 18 | (zvmvlpfhxd) = 18 patients reported treatment-related adverse events (TRAE), most commonly alopecia (66.7%), nausea (66.7%), and vomiting (50%). The most common grade 3-4 TRAEs were neutropenia (33.3%), leukopenia (22.2%), and anemia (16.7%), all of which recovered after symptomatic treatment. No AE leading to death occurred during the study. odjuvedlcn (uskululjhb ) | - | 25 Sep 2021 | |||
Phase 2 | 59 | (wamuwdzxzx) = usgkqwamne jnnpyqotfz (rfmlsyadyz ) View more | Positive | 06 Dec 2023 | |||
(high TROP2 expression) | (wamuwdzxzx) = zjwlwnlzps jnnpyqotfz (rfmlsyadyz ) View more | ||||||
NCT04152499 (ESMO2023) Manual | Phase 1/2 | Hormone receptor positive HER2 negative breast cancer HR positive | HER2 negative | 41 | (ynfdkaihxu) = chaloboxux xnjyfqcicj (fxzrfiuelc ) View more | Positive | 22 Oct 2023 | |
Phase 2 | Gastrooesophageal junction cancer Second line | Third line | 48 | SKB264 5 mg/kg Q2W | (jvrujqwpcm) = bldycfznhk fwqvcfonwg (eotpvfuwkh ) View more | - | 05 Apr 2024 | |
Phase 2 | 43 | (gnyohsqqpg) = scwkvqpnke tshcmoosse (wpklzkuooa ) View more | Positive | 05 Apr 2024 | |||
(EGFR mutant) | (gnyohsqqpg) = dsoeuhdprl tshcmoosse (wpklzkuooa ) View more |